Home Depot Inc (HD) Stock Price Today
Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Life360 director Morin Brit sells 15,582 shares for $1 million
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
Airbus leads aerospace market with strong orders despite production challenges
Airbus is outperforming Boeing in commercial aircraft orders, securing 821 net orders in H1 2026 compared to Boeing's 408. Morgan Stanley maintains an "Overweight" rating on Airbus, raising its price target to €255, reflecting confidence in the compa...
Danaher seen as a Buy with growth set to rebound in 2027 as respiratory issues ease and bioprocessing recovers.
Danaher is rated a Buy due to expected acceleration in revenue growth by 2027, driven by fading respiratory business challenges and recovery in bioprocessing shipments. Its valuation is attractive, trading at a 12% discount to its five-year average P...
CFTC reviews prediction markets on word mentions, prompting Kalshi to remove sports-related contracts.
The Commodity Futures Trading Commission (CFTC) is reviewing 'mention markets' on prediction platforms, where traders bet on whether specific words will be used in speeches or broadcasts. In response, Kalshi removed its sports-related mention markets...
JPMorgan's Nasdaq-based fund outperforms sibling with higher premiums but risks remain.
JPMorgan's Nasdaq Equity Premium Income ETF (JEPQ) has significantly outperformed its sibling, the JPMorgan Equity Premium Income ETF (JEPI), due to its strategy of writing call options against the Nasdaq-100, which has higher implied volatility and ...
Target's stock may face a pullback despite strong Q2 earnings forecast and 57% YTD surge.
Target is expected to report second-quarter earnings of $2.25 per share, a 9.8% increase from last year, with revenues projected at $26.06 billion, up 3.4%. Despite these positive forecasts, the stock has surged 57% year-to-date, leading an analyst t...
OpenAI's enterprise revenue surpasses consumer, hitting $40B run rate amid exec changes
OpenAI's CFO Sarah Friar reported that enterprise revenue now exceeds consumer revenue, with an annualized run rate of $40 billion, surpassing earlier forecasts. This growth comes despite recent executive departures, including revenue chief Denise Dr...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.